arrow_back Back to App

More Transparency in Drug Approvals

New rules require the government to explain why certain drugs were approved quickly. This information will be publicly available, helping citizens understand the decision-making process for medications.
Key points
Requires public explanation for the basis of accelerated approval for certain drugs.
Information will include the rationale for using early indicators of effectiveness instead of full clinical data.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_4390
Sponsor: Sen. Hickenlooper, John W. [D-CO]
Process start date: 2022-06-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-04-17
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Accelerated Approval Transparency Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_4390.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-06-14.

What are the main provisions?

Key points include:

  • Requires public explanation for the basis of accelerated approval for certain drugs.
  • Information will include the rationale for using early indicators of effectiveness instead of full clinical data.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Hickenlooper, John W. [D-CO].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health